Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Morabito F, Tripepi G, Mauro FR, Laurenti L, Reda G, Moia R, Condoluci A, Vincelli I, Chiarenza A, Vigna E, Martino EA, Bruzzese A, Mezzatesta S, Laureana R, Cutrona G, Di Raimondo F, Fronza G, Zucchetto A, Bomben R, Rossi FM, Olivieri J, Zaja F, Rossi D, Gaidano G, Del Principe MI, Ilariucci F, Del Poeta G, Ferrarini M, Neri A, Gattei V, Gentile M. Morabito F, et al. Among authors: di raimondo f. Am J Hematol. 2023 Jul;98(7):E157-E160. doi: 10.1002/ajh.26927. Epub 2023 Apr 17. Am J Hematol. 2023. PMID: 37067157 No abstract available.
Effects of imatinib mesylate in osteoblastogenesis.
Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F. Tibullo D, et al. Among authors: di raimondo f. Exp Hematol. 2009 Apr;37(4):461-8. doi: 10.1016/j.exphem.2008.12.008. Exp Hematol. 2009. PMID: 19302920 Free article.
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience.
Molica S, Di Raimondo F, Cutrona G, Fabris S, Mauro F, Brugiatelli M, Baldini L, Musto P, Sacchi S, Cortelezzi A, Foà R, Neri A, Federico M, Ferrarini M, Morabito F; Gruppo Italiano Studio Linfomi (GISL). Molica S, et al. Among authors: di raimondo f. Leuk Res. 2010 Aug;34(8):e217-8. doi: 10.1016/j.leukres.2010.03.014. Epub 2010 Mar 31. Leuk Res. 2010. PMID: 20359746 No abstract available.
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, Palumbo GA, Di Raimondo F. Giallongo C, et al. Among authors: di raimondo f. Eur J Haematol. 2011 Mar;86(3):216-25. doi: 10.1111/j.1600-0609.2010.01570.x. Epub 2011 Feb 8. Eur J Haematol. 2011. PMID: 21198861
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.
Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A, Gattei V. Dal Bo M, et al. Among authors: di raimondo f. Genes Chromosomes Cancer. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. Epub 2011 May 11. Genes Chromosomes Cancer. 2011. PMID: 21563234
Primary plasma cell leukemia in the era of new drugs: has something changed?
Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P, Bringhen S, Offidani M, Omede' P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M, Palumbo A. Musto P, et al. Among authors: di raimondo f. Crit Rev Oncol Hematol. 2012 May;82(2):141-9. doi: 10.1016/j.critrevonc.2011.04.005. Epub 2011 Jun 29. Crit Rev Oncol Hematol. 2012. PMID: 21719304
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia.
Maura F, Cutrona G, Fabris S, Colombo M, Tuana G, Agnelli L, Matis S, Lionetti M, Gentile M, Recchia AG, Di Raimondo F, Musolino C, Ilariucci F, Di Renzo N, Pesce E, Molica S, Federico M, Cortelezzi A, Morabito F, Ferrarini M, Neri A. Maura F, et al. Among authors: di raimondo f, di renzo n. PLoS One. 2011;6(8):e24313. doi: 10.1371/journal.pone.0024313. Epub 2011 Aug 29. PLoS One. 2011. PMID: 21897877 Free PMC article.
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. Morabito F, et al. Among authors: di raimondo f. Blood. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27. Blood. 2011. PMID: 21951682 Free article. Clinical Trial.
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.
Elia L, Grammatico S, Paoloni F, Vignetti M, Rago A, Cenfra N, Mecarocci S, Mancini M, Luciani M, Di Raimondo F, Cazzaniga G, Matarazzo M, Moleti ML, Santoro L, Gaidano G, Foà R, Mandelli F, Cimino G. Elia L, et al. Among authors: di raimondo f. Am J Hematol. 2011 Dec;86(12):993-7. doi: 10.1002/ajh.22161. Epub 2011 Sep 22. Am J Hematol. 2011. PMID: 21953510 Free article.
473 results